Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
Conclusion: The evaluation of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity was concluded to show no meaningful clinical difference of the biosimilar omalizumab with the reference product.
PMID: 33247645 [PubMed - as supplied by publisher]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
More News: Allergy & Immunology | Asthma | Corticosteroid Therapy | General Medicine | India Health | Statistics | Study | Xolair